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Introduction
An increase in body fat is generally associated with
an increase in risk of metabolic diseases such as type
2 diabetes mellitus, hypertension and dyslipidaemia
(1). Body mass index (BMI) criteria are currently the
primary focus in obesity treatment recommenda-
tions, with different treatment cutoff points based
upon the presence or absence of obesity-related
comorbid disease (Table 1). In addition, many
patients with these metabolic diseases are either over-
weight or obese. While these simple clinical concepts
may be well-accepted among many clinicians and
researchers, and assumed to be readily accessible in
the medical literature, the authors are unaware of
any previous reports in which data regarding the
important relationship between BMI and metabolic
disease are summarised in a comprehensive manner.
Deﬁning the relationship between body weight and
metabolic disease is critical toward a better under-
standing of the underlying pathophysiological pro-
cesses leading to excessive fat-related metabolic
disease.
Health information regarding such relationships is
often obtained through the use of surveys. Popula-
tion surveys are a well-recognised, and much utilised
method to assess the prevalence of diseases as well as
obtain other health-related information (2–4). One
of the more recognised survey measures are the
National Health and Nutrition Examination Surveys
(NHANES) (4,5), which have incorporated subjective
survey data obtained from interviews, along with
additional data derived from objective clinical assess-
ment and laboratory data. Patient-reported surveys
OnlineOpen:This article is available free online at www.blackwell-synergy.com             
SUMMARY
The objectives of this study were to explore the relation between body mass index
(BMI) and prevalence of diabetes mellitus, hypertension and dyslipidaemia; exam-
ine BMI distributions among patients with these conditions; and compare results
from two national surveys. The Study to Help Improve Early evaluation and man-
agement of risk factors Leading to Diabetes (SHIELD) 2004 screening questionnaire
(mailed survey) and the National Health and Nutrition Examination Surveys
(NHANES) 1999–2002 (interview, clinical and laboratory data) were conducted in
nationally representative samples ‡ 18 years old. Responses were received from
127,420 of 200,000 households (64%, representing 211,097 adults) for SHIELD,
and 4257 participants for NHANES. Prevalence of diabetes mellitus, hypertension
and dyslipidaemia was estimated within BMI categories, as was distribution of BMI
levels among individuals with these diseases. Mean BMI was 27.8 kg/m
2 for
SHIELD and 27.9 kg/m
2 for NHANES. Increased BMI was associated with increased
prevalence of diabetes mellitus, hypertension and dyslipidaemia in both studies
(p < 0.001). For each condition, more than 75% of patients had BMI ‡ 25 kg/m
2.
Estimated prevalence of diabetes mellitus and hypertension was similar in both
studies, while dyslipidaemia was substantially higher in NHANES than SHIELD. In
both studies, prevalence of diabetes mellitus, hypertension and dyslipidaemia
occurred across all ranges of BMI, but increased with higher BMI. However, not all
overweight or obese patients had these metabolic diseases and not all with these
conditions were overweight or obese. Except for dyslipidaemia prevalence, SHIELD
was comparable with NHANES. Consumer panel surveys may be an alternative
method to collect data on the relationship of BMI and metabolic diseases.
What’s known
An increase in body fat is generally associated with
increased risk of metabolic diseases such as type 2
diabetes mellitus, hypertension and dyslipidaemia.
However, not all overweight or obese patients have
metabolic diseases, and vice versa. While these
concepts may be well-accepted, and assumed to be
readily accessible in the literature, the authors are
unaware of any single report presenting
comprehensive data regarding the relationship
between BMI and metabolic diseases.
What’s new
Deﬁning the relationship between body weight and
metabolic diseases is critical toward better
understanding of the underlying pathophysiological
processes leading to these diseases. Data from the
two national surveys reported here support the
common clinical observation that patients with
higher BMI are at higher risk for having diabetes
mellitus, hypertension and dyslipidaemia. They also
conﬁrm the converse – the majority of patients
with these metabolic diseases are either overweight
or obese.
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large sample sizes and providing access to data that
may otherwise be difﬁcult to obtain.
In this study, data from two national surveys were
evaluated to determine the relationship between dif-
ferent BMI categories and the prevalence of diabetes
mellitus, hypertension and dyslipidaemia. The Study
to Help Improve Early evaluation and management
of risk factors Leading to Diabetes (SHIELD) was a
self-reported survey (with no clinical or laboratory
evaluation) conducted in 2004 that assessed the
association of different BMI categories with diabetes
mellitus, hypertension and dyslipidaemia. The com-
parator survey was the NHANES 1999–2002, which
obtained data through interviewer-administered sur-
veys, as well as clinical evaluations and laboratory
assessments (4,5).
The objectives of this study were to: (i) explore
the relation between BMI level and prevalence of dia-
betes mellitus, hypertension and dyslipidaemia; (ii)
examine the distribution of BMI levels among people
with these conditions; and (iii) compare the results
on these measures between these two national sur-
veys (SHIELD and NHANES).
Methods
SHIELD survey
The SHIELD screening survey was mailed in April
2004 to a stratiﬁed random sample of 200,000 US
households who were part of the Taylor Nelson
Sofres National Family Opinion, Inc. (TNS NFO,
Greenwich, CT, USA) household survey panel (no
monetary or other inducement was offered for com-
pleting and returning the screening questionnaire).
TNS NFO is a market research ﬁrm that has collec-
ted a survey panel of more than 600,000 house-
holds, whose only requirements for participation
include being ‡18 years of age and having a tele-
phone and mailing address. Stratiﬁed random sam-
ples of households (selected to be representative of
the US population based on US census data for age,
gender, income, household size, urban density and
census region) are invited to enrol in the panel, and
demographic information is obtained from those
who enrol (and updated every 2 years). This panel
methodology both minimises sample bias because of
high response rates, and allows us to understand
the demographics of survey non-responders (which
random population sampling would not allow).
Households who agree to participate are invited to
take part in periodic surveys.
Because prospective stratiﬁcation was performed
to ensure that the survey panel represented the US
population in terms of geographic residence, age of
the head of household, and household size and
income, the SHIELD screening survey could provide
self-reported prevalence estimates at a national level.
Previous NFO panel surveys have been used to calcu-
late the population prevalence of conditions such as
migraine (6) and bipolar disorder (2).
Once received, the screening survey was completed
by the head of household, who answered for up to
four adult (18 years of age or older) household
members. This survey consisted of a 12-item ques-
tionnaire developed by a diversiﬁed panel of experts
(the SHIELD Survey Group). Demographic informa-
tion was requested as well as other data about the
respondent and other adult family members, such as
whether a healthcare professional had ever told them
they had diabetes mellitus, high blood pressure or
problems with cholesterol. Judging that many, if not
most respondents to a self-administered question-
naire may be unable to recall their actual fasting
plasma glucose (FPG) results, blood pressure or
cholesterol levels, respondents were asked if they had
Table 1 Adaptation of the 1998 National Heart, Lung and Blood Institute – National Institutes of Health Clinical Guidelines on the
identiﬁcation, evaluation and treatment of overweight and obesity in adults
Risk category
BMI at which no
intervention
recommended (kg/m
2)
BMI to initiate low-calorie diet,
physical activity and
behavioural therapy (kg/m
2)
BMI to consider drug
treatment* (kg/m
2)
BMI to consider
surgery† (kg/m
2)
With comorbidities 18.5–24.9 BMI ‡ 25 BMI ‡ 27 ‡ 35
Without comorbidities 18.5–24.9 BMI ‡ 25§ BMI ‡ 30 ‡ 40
Reprinted with permission from (24). *Drug treatment can be considered if after 6 months of lifestyle therapy, there is inadequate weight loss. Drugs should be used
only as part of a programme that includes diet, physical activity and behaviour therapy. Although not mandatory, surgery for obesity is considered a treatment
option, if medically appropriate, and is reserved for patients in whom efforts at medical therapy have failed and who are suffering from the complications of extreme
obesity. Comorbidities include two or more of obesity-related hypertension, dyslipidaemia, CHD, type 2 diabetes mellitus and obstructive sleep apnoea. §If no
comorbidities are present, and BMI ‡ 25 but < 30 kg/m
2, low-calorie diet, physical activity and behavioural therapy is recommended only if patient ‘wants’ to lose
weight. Otherwise, the patient is advised to maintain weight and address other risk factors. BMI, body mass index.
Plough, Metabasis Therapeutics, Micr-
obia, Novartis, Nicox, Ortho-McNeil,
Parke Davis, Pﬁzer, Roche, Sandoz,
Sankyo, Sanoﬁ Aventis, Shering
Plough, SmithKline Beacham, Takeda,
UpJohn and Warner Lambert.
Dr Grandy is an employee of Astra-
Zeneca LP.
738 Relation of BMI to diabetes mellitus
ª 2007 The Authors AstraZeneca Pharmaceuticals LP Int J Clin Pract, May 2007, 61, 5, 737–747ever been diagnosed as having, or were currently
taking prescription medications for, diabetes mellitus,
high blood pressure or cholesterol problems.
Respondents were also asked to provide their weight
and height, which were used to calculate BMI.
Once the screening questionnaires were comple-
ted and returned, samples of respondents with dia-
betes mellitus or risk factors for diabetes mellitus
were then sent a longer, more detailed survey in
August 2004 (with annual follow-up assessments
planned over the subsequent 4 years) to determine
the longitudinal relationship of demographics,
comorbid conditions, health status, knowledge, atti-
tudes, current behaviours and treatments toward
the progression or onset of diabetes mellitus. The
analysis described in this study focused only on
the SHIELD data obtained from the 2004 screening
survey.
NHANES 1999–2002 survey
Data from the SHIELD survey were compared with
data derived from NHANES 1999–2002, which rep-
resents the fourth round of this national survey.
NHANES is an annual survey that produces
nationally representative data about the health and
nutritional status of the US civilian non-institu-
tionalised population. In NHANES, potential par-
ticipants are selected through a complex statistical
process using the most current US Census infor-
mation. After agreeing to take part in the survey,
and after it has been determined that they qualify,
NHANES participants undergo a 1-h ‘in-home’
interview consisting of subjective survey questions
regarding health, disease history and diet. After-
ward, participants go to a local Mobile Exam Cen-
ter, where objective health measurements, physical
examinations and laboratory tests are performed
based upon age and gender (7). Thus, NHANES
includes both self-reported diagnosed conditions as
well as clinical evaluation and laboratory testing
to conﬁrm diagnoses and to identify undiagnosed
conditions. For example, the prevalence of diabetes
mellitus can be calculated based on both the
interview data (e.g. Have you ever been told by a
physician that you have diabetes?) as well as labor-
atory glucose values. Details of the NHANES data
collection are disseminated by the National Center
for Health Statistics (NCHS) (4,5). Because the
NHANES data include laboratory values along with
diagnoses and treatments, it can be used with a
weighting system to estimate actual national
prevalence of various conditions.
In this study, NHANES data on adults 18 years of
age or older were analysed to determine the prevalence
(self-reported plus laboratory test conﬁrmed) of
diabetes mellitus, hypertension and dyslipidaemia
across different BMI ranges, as well as the distribu-
tion of BMI among those with these metabolic dis-
eases.
Deﬁnitions used to identify conditions
For SHIELD, the diagnoses of diabetes mellitus
(type 1 or 2), hypertension and dyslipidaemia were
identiﬁed solely on the basis of self-reporting by
respondents who recorded on the screener that a
healthcare professional had diagnosed the condition
(i.e. conditions that you/other adult household
members have ever been told you have by a doc-
tor or nurse). For comparison with NHANES,
which does not distinguish between type 1 and 2
diabetes mellitus, the total self-reported diabetes
mellitus prevalence is reported here. BMI was cal-
culated as weight in kilograms divided by the
square of height in metres, again, using only self-
reported height and weight.
For NHANES, deﬁnitions were intended to be
consistent with those used in prior analyses (8,9). In
building each analysis variable, cases with missing
data on any of the components that were used to
create the analysis variable were excluded. The
NHANES deﬁnitions utilised in this study are listed
below.
Body mass index
Calculated from height and weight (kg/m
2) measured
using standardised examination protocols (7).
Diabetes mellitus
Deﬁned to include both previously diagnosed and
undiagnosed diabetes mellitus (type 1 or 2). Diag-
nosed diabetes mellitus was based on self-reported
responses (i.e. respondent answered yes to ‘Has a
doctor ever told you that you have diabetes?’). Undi-
agnosed diabetes mellitus was deﬁned using the
American Diabetes Association criterion of FPG
> 125 mg/dl (7.0 mmol/l) (10).
Hypertension
Deﬁned to include patients with history of taking
antihypertensive medication, or elevated blood pres-
sure (using Seventh Report of the Joint National
Committee on Prevention, Detection, Evaluation and
Treatment of High Blood Pressure criteria of systolic
pressure of at least 140 mmHg or diastolic pressure
of at least 90 mmHg) (11). Blood pressure measures
in NHANES were based on the average of blood
pressure measurements taken; in 1999–2002, 78% of
NHANES participants had at least three blood pres-
sure readings taken (the remaining 22% had fewer
than three readings available).
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Deﬁned to include any one of the following: total
cholesterol (TC) ‡ 240 mg/dl (6.22 mmol/l), triglyc-
erides (TG) > 200 mg/dl (2.26 mmol/l), low-density
lipoprotein cholesterol (LDL-C) ‡ 160 mg/dl (4.14
mmol/l) or high-density lipoprotein cholesterol
(HDL-C) < 40 mg/dl (1.04 mmol/l), as well as those
ever told by a doctor or other healthcare professional
that their blood cholesterol level was high. Other
lipid parameters, such as non-HDL-C, apolipopro-
tein B, lipoprotein (a), abnormalities in lipoprotein
particle size and subclass distribution, etc., were not
reported in NHANES.
No consideration of coronary heart disease (CHD)
risk factors was included in the deﬁnition of dysli-
pidaemia with NHANES because data on several spe-
ciﬁc risk factors was not available from SHIELD
data. Other categories, such as prehypertension or
hyperinsulinaemia, were also not examined because
these conditions were not collected in the SHIELD
survey.
Statistical analysis
The prospective stratiﬁcation sampling used in
SHIELD allowed performance of postweighting of the
data to correct for over- or under-sampling of some
demographic groups and to ensure that the respond-
ents represented the US Census population (12) in
terms of geographic residence, age of the head of
household, and household size and income. No
attempt was made to remove outliers from the self-
reported data. Similarly, NHANES prevalence esti-
mates were calculated using NCHS sampling weights
(based on age, income and race/ethnicity) to represent
the US adult population. The entire dataset time span
(1999–2002) was used to create national prevalence
estimates because estimates based on individual survey
phases may vary. Neither survey was postweighted for
parameters other than demographic data.
Using the weighted responses for this analysis, we
constructed a matrix to compare BMI levels with the
prevalence of diabetes mellitus, hypertension and
dyslipidaemia, as well as to identify the population
distribution of BMI levels among individuals with
these metabolic diseases. BMI was categorised using
cut-points derived from the 1998 National Heart,
Lung and Blood Institute Guidelines (13) with
respondents allocated into one of seven categories
(< 18.5, 18.5–24.9, 25.0–26.9, 27.0–29.9, 30.0–34.9,
35.0–39.9 and ‡ 40 kg/m
2). We then compared the
population distributions of BMI derived from
SHIELD and NHANES.
For each survey, tests for linear trend across BMI
categories were performed using a series of logistic
regression analyses, with each condition as the
dependent variable and the midpoint of each BMI
category as the only independent variable. These ana-
lyses tested whether prevalence of each condition
increased as BMI increased, by examining the Wald
statistic for the BMI coefﬁcient in each regression
model (p-values <0.05 were considered statistically
signiﬁcant).
For each condition, prevalence estimates from
SHIELD and NHANES within each BMI category
were compared using chi-squared tests, with p-values
<0.05 considered signiﬁcant. Analyses of the SHIELD
data were conducted using SPSS for Windows
(release 13.0.1; SPSS Inc., Chicago, IL) and WesVar
(version 4.2; Westat, Rockville, MD). Analyses in
NHANES were performed using SUDAAN
(SUDAAN: Software for the Statistical Analysis of
Correlated Data, release 9.0; Research Triangle Insti-
tute, Research Triangle Park, NC). The WesVar and
SUDAAN software programs account for the com-
plex stratiﬁcation procedures and clustering (e.g. at
the household level) used in these surveys, to ensure
proper sample weighting and estimation of variance.
Variance estimation methods were used to calculate
the standard errors, accounting for both the complex
sample design and, in NHANES, the use of both
interview and morning examination sample data in
combination (4,5).
Results
The SHIELD screener questionnaire was sent to
200,000 households; 127,420 were returned with
usable surveys, yielding a response rate of 64% (pub-
lished reviews have found mean response rates of
approximately 67–68% for mailed surveys) (14,15).
Each questionnaire was completed for up to four
adults per household; therefore, the returned screener
questionnaires contained data on 211,097 adults. The
response rate for completed examinations in
NHANES 1999–2002 was 76.3% (9282/12,160). A
subsample of NHANES respondents (n ¼ 4257) were
selected to fast eight or more hours (up to 24) for
laboratory testing (e.g. FPG).
Comparison of SHIELD and NHANES data
As Figure 1 shows, the patients represented by these
surveys had similar distributions of BMI, with mean
(± standard deviation) of 27.8 kg/m
2 (± 6.8) (med-
ian ¼ 26.6 kg/m
2) for SHIELD and 27.9 kg/m
2
(± 6.2) (median ¼ 26.8 kg/m
2) for NHANES. The
estimated prevalence of diabetes mellitus and hyper-
tension within each BMI category was similar in the
SHIELD and NHANES participants (Figures 2 and 3),
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Figure 1 Distributions of body mass
index (BMI) in Study to Help Improve
Early evaluation and management of risk
factors Leading to Diabetes (SHIELD)
and National Health and Nutrition
Examination Surveys (NHANES)
0
5
10
15
20
25
30
<18.5
18.5–24.9
25.0–26.9
27.0–29.9
30.0–34.9
35.0–39.9
BMI category (kg/m2)
P
e
r
c
e
n
t
 
(
%
)
SHIELD NHANES
Figure 2 Prevalence of diabetes mellitus (types 1 and 2) by body mass index (BMI) level*. *p < 0.001 in tests of linear
trend across BMI groups within each study [Study to Help Improve Early evaluation and management of risk factors
Leading to Diabetes (SHIELD) and National Health and Nutrition Examination Surveys (NHANES)]; p < 0.001 in tests
comparing SHIELD with NHANES estimates (for each BMI category)
0.0
10.0
20.0
30.0
40.0
50.0
60.0
<18.5
18.5–24.9
25.0–26.9
27.0–29.9
30.0–34.9
35.0–39.9
BMI category (kg/m2)
P
e
r
c
e
n
t
 
(
%
)
SHIELD NHANES
Figure 3 Prevalence of hypertension by body mass index (BMI) level*. *p < 0.001 in tests of linear trend across BMI
groups within each study [Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes
(SHIELD) and National Health and Nutrition Examination Surveys (NHANES)]; p < 0.001 in tests comparing SHIELD
with NHANES estimates (for each BMI category)
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higher in NHANES than in SHIELD. All comparisons
between SHIELD and NHANES estimates within BMI
category were statistically signiﬁcant (p < 0.001 in
chi-squared tests), largely because of the large sample
sizes involved, but the practical signiﬁcance of
these differences for diabetes mellitus and hyperten-
sion is minimal. In contrast, the prevalence of dyslipi-
daemia was substantially higher across all BMI levels
in NHANES compared with SHIELD (Figure 4).
Relationship of BMI level to prevalence of
diabetes mellitus, hypertension and
dyslipidaemia
Both surveys showed that an increase in BMI is gener-
ally associated with a signiﬁcant increase in prevalence
of diabetes mellitus, hypertension and dyslipidaemia
(p < 0.001 for all in tests for linear trend across BMI
groups). However, these metabolic diseases were
present at all levels of BMI (Figures 2–4). The preval-
ence of diabetes mellitus and hypertension increased
in an observable, linear fashion as BMI levels
increased. The prevalence of diabetes mellitus was
highest among morbidly obese individuals (BMI
‡ 40 kg/m
2), with rates of 25% (SHIELD) and 27%
(NHANES). The same was true for hypertension, with
highest prevalence among morbidly obese individuals
(49% in SHIELD; 51% in NHANES).
Somewhat in contrast, while there was a signiﬁ-
cant increasing trend towards higher prevalence of
dyslipidaemia as BMI increased, once BMI reached
30 kg/m
2 or more, this increasing trend was blunted
and the likelihood of participants having self-repor-
ted or laboratory-conﬁrmed dyslipidaemia had less
direct relationship to increasing BMI category
than was seen for diabetes mellitus or hypertension
(Figure 4). At the very highest levels of BMI, the
prevalence of dyslipidaemia levelled off in the
obese and morbidly obese groups in the SHIELD
data (35–36%) and actually declined in the NHANES
data (68–63%).
These increasing trends meant that conditions also
tended to co-occur at higher BMI levels. For exam-
ple, in NHANES 1999–2002 data, approximately
80% of those with BMI ‡ 35 kg/m
2 had one or
more of these metabolic diseases, compared with
only 36% of those with BMI < 18.5 kg/m
2 having
one or more of these metabolic diseases.
Distribution of BMI levels among those with
diabetes mellitus, hypertension and
dyslipidaemia
The above data reﬂect the prevalence of metabolic
disease with increasing BMI. But patients were also
evaluated with regard to the relative distribution of
BMI levels among those who had metabolic diseases:
speciﬁcally diabetes mellitus, hypertension and dysli-
pidaemia. In general, the BMI ranges of patients with
diabetes mellitus, hypertension and dyslipidaemia
were similar between SHIELD and NHANES.
Figure 5 (Table 2) shows the BMI distributions
observed in SHIELD and NHANES among adults
with diabetes mellitus. The majority of adults with
diabetes mellitus were obese (BMI ‡ 30 kg/m
2; 59%
for SHIELD and 51% for NHANES). When BMI
‡ 25 kg/m
2 (the cut-off point for ‘overweight’) was
applied, this percentage increased to 87% for
SHIELD and 82% for NHANES, meaning that 13%
of SHIELD and 18% NHANES diabetes mellitus
patients were not overweight or obese.
Similarly, the prevalence of excessive body weight
was also high in patients with hypertension (Figure 6,
Table 2). Approximately 46% of SHIELD and 55%
of NHANES hypertensive patients were obese, and
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Figure 4 Prevalence of dyslipidaemia by body mass index (BMI) level*. *p < 0.001 in tests of linear trend across BMI
groups within each study [Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes
(SHIELD) and National Health and Nutrition Examination Surveys (NHANES)]; p < 0.001 in tests comparing SHIELD
with NHANES estimates (for each BMI category)
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patients were overweight or obese. Twenty per cent
of SHIELD and 15% of NHANES hypertensive
patients had a BMI < 25 kg/m
2, and therefore would
be considered to be normal weight or underweight
(1,13).
With regard to dyslipidaemia (Figure 7, Table 2),
again, a high prevalence of obesity was found in
patients who had at least one of four criteria for the
diagnosis of ‘dyslipidaemia’ (as described above in
‘Deﬁnitions used to identify conditions’); 38% of
SHIELD and 52% of NHANES dyslipidaemic
patients were obese, while 75% of SHIELD and 84%
of NHANES dyslipidaemic patients were overweight
or obese. However, 25% of SHIELD and 16% of
NHANES dyslipidaemic patients were not over-
weight.
Comment
Data from both the SHIELD and NHANES surveys
reported here reﬂect and support the common clin-
ical observation that patients with higher BMI are at
higher risk for having diabetes mellitus, hypertension
and dyslipidaemia. It also conﬁrms the converse –
that the majority of patients with these metabolic
diseases are either overweight or obese. These results
provide nationally representative data regarding the
important relationship between BMI and these meta-
bolic diseases. Finally, this analysis suggests that a
self-reported only survey such as SHIELD may often
provide useful and reasonably reliable information
when compared with a ‘gold standard’ survey that
also includes clinical evaluation and laboratory con-
ﬁrmation, such as NHANES. The exception to this is
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Figure 5 Relative distributions of body mass index (BMI) in Study to Help Improve Early evaluation and management of
risk factors Leading to Diabetes (SHIELD) and National Health and Nutrition Examination Surveys (NHANES)
respondents with diabetes mellitus (types 1 and 2)
Table 2 Relative distributions of body mass index (BMI) in SHIELD and NHANES respondents with diabetes mellitus
(types 1 and 2), hypertension and dyslipidaemia
BMI category
(kg/m
2)
Diabetes mellitus
(types 1 and 2) Hypertension Dyslipidaemia
SHIELD NHANES SHIELD NHANES SHIELD NHANES
< 18.5 0.5 0.4 0.9 0.3 1.0 0.4
18.5–24.9 12.2 17.1 19.6 14.6 23.8 16.1
25.0–26.9 10.3 9.9 13.7 7.2 15.9 7.1
27.0–29.9 17.8 21.7 20.2 23.5 21.4 24.5
30.0–34.9 26.1 23.2 23.6 26.0 21.3 23.5
35.0–39.9 15.5 13.9 11.7 13.5 9.3 13.7
‡ 40.0 17.6 13.8 10.4 15.1 7.3 14.7
NHANES, National Health and Nutrition Examination Surveys; SHIELD, Study to Help Improve
Early evaluation and management of risk factors Leading to Diabetes.
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values, especially when multiple deﬁned variables
are involved, as in the data reported here concerning
dyslipidaemia.
The BMI distributions in SHIELD and NHANES
were remarkably similar (Figure 1), in large part
likely because of the fact that both the SHIELD and
NHANES responses were weighted to match the US
adult population, and because other epidemiologic
studies have demonstrated that self-reported height
and weight accurately correlated with measured
height and weight (16,17). Similarly, both SHIELD
and NHANES consistently demonstrated an increase
in prevalence of type 2 diabetes mellitus and hyper-
tension with increasing BMI, with reported per-
centage rates across various BMI ranges that were also
remarkably similar (Figures 2 and 3).
Additionally, both SHIELD and NHANES demon-
strated gradual increases in dyslipidaemia until the
BMI reached above 30 kg/m
2 (Figure 4). Beyond this,
the prevalence peaked, and in fact estimates began to
decline in NHANES. The prevalence of dyslipidaemia
in NHANES was higher at each cut-off point when
compared with SHIELD. This is likely related to the
SHIELD 
1.0 
23.8 
15.9 
21.4 
21.3 
9.3 
7.3 
NHANES 
0.4 
16.1 
7.1
24.5 
23.5 
13.7 
14.7 
<18.5  18.5–24.9  25.0–26.9  27.0–29.9 
30.0–34.9  35.0–39.9 
Figure 7 Relative distributions of body mass index (BMI) in Study to Help Improve Early evaluation and management of
risk factors Leading to Diabetes (SHIELD) and National Health and Nutrition Examination Surveys (NHANES)
respondents with dyslipidaemia
NHANES 
0.3 
14.6 
7.2 
23.5
26.0 
13.5 
15.1 
SHIELD 
0.9 
19.6 
13.7 
20.2 
23.6 
11.7 
10.4 
<18.5  18.5–24.9  25.0–26.9  27.0–29.9 
30.0–34.9  35.0–39.9 
Figure 6 Relative distributions of body mass index (BMI) in Study to Help Improve Early evaluation and management of
risk factors Leading to Diabetes (SHIELD) and National Health and Nutrition Examination Surveys (NHANES)
respondents with hypertension
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only history, but also four laboratory values (TC,
TG, LDL-C and HDL-C levels). An abnormality of
any of these individual variables would have been
recorded as ‘dyslipidaemia’. Given that NHANES
included laboratory testing and SHIELD did not, it
is thus not surprising that the prevalence of dyslipi-
daemia was reportedly higher in NHANES. Had dysli-
pidaemia been deﬁned as one variable, such as an
increase in LDL-C level only, then the prevalence of
dyslipidaemia in NHANES would likely have been
less, and the differences in the reported prevalence
of dyslipidaemia between SHIELD and NHANES
would have been closer. Conversely, it should be
noted that the lipid level values that were chosen to
deﬁne ‘dyslipidaemia’ in this study were conservative.
Had more aggressive cut-off levels been used to
deﬁne ‘dyslipidaemia,’ such as TC ‡ 200, TG ‡ 150,
LDL-C ‡ 100 or HDL-C < 60 mg/dl, instead of the
deﬁnition of dyslipidaemia used in this analysis
(TC ‡ 240, TG > 200, LDL-C ‡ 160 or HDL-C
< 40 mg/dl), then the diagnosis of dyslipidaemia in
NHANES would have been greater, and the differ-
ences between the prevalence of dyslipidaemia in
SHIELD and NHANES would have been even
greater. Hence, the degree of correlation of ‘dyslipi-
daemia’ in a self-reported survey (such as SHIELD)
compared with that of an objective survey that
includes laboratory assessment (such as NHANES),
and that is performed on a wide spectrum of partici-
pants (without regard to their CHD risk) is thus
largely dependent upon how the dyslipidaemia is
deﬁned.
With regard to the analysis of patients with diabe-
tes mellitus, hypertension or dyslipidaemia, whether
it was data collected through a self-reported survey
only (such as SHIELD) or through a more detailed
evaluation (NHANES), 75% or more of patients with
each of these individual metabolic diseases (often
thought to be ‘obesity related’) were overweight or
obese, while about 10–25% were not overweight. In
fact, some prevalence of metabolic diseases was
reported at all BMI levels. Collectively, the ﬁndings
presented here document that, while often directly
related, not all overweight or obese patients have dia-
betes mellitus, hypertension or dyslipidaemia, and
that not all patients with these metabolic diseases are
overweight or obese. This simple message has pro-
found implications as to the pathophysiologic rela-
tionship between fat and metabolic disease (18–20),
such as whether, from the standpoint of excessive
fat-related metabolic diseases, it is best to focus on
fat mass (adiposity) alone (Table 1), or whether a
focus on the pathogenic potential of adipose tissue
(adiposopathy) might also be warranted (20–27).
In other words, whether or not weight gain may
cause or worsen metabolic disease (25) and whether
or not weight loss may improve metabolic disease
(26) are very much dependent upon the effects on
the pathogenic potential of adipose tissue. For exam-
ple, positive caloric balance is most likely to result in
metabolic disease when accompanied by: (i) impaired
adipogenesis, which limits energy storage potential,
resulting in excessive adipocyte hypertrophy which
adversely affects adipocyte/adipose tissue dysfunction;
(ii) accumulation and hypertrophy of visceral fat,
hypertrophy of peripheral fat and increases in intra-
organ fat (such as in the liver, muscle or pancreas),
which result in adverse metabolic and immunologic
consequences; (iii) impaired nutrient metabolism
such as a net increase in free fatty acids, which is
lipotoxic to body organs such as muscle, liver and
pancreas; (iv) adipocyte and adipose tissue dysfunc-
tion which results in adverse metabolic consequences,
because adipose tissue is an active endocrine organ
(v) adipocyte and adipose tissue dysfunction which
results in adverse immunological consequences,
because adipose tissue is an active immune organ,
and (vi) disruption of optimal interorgan ‘cross-talk’
of adipose tissue with other body organs, because
metabolic diseases associated with positive caloric
balance are most often caused by a pathologic part-
nership between the dysfunction and/or limitations
of adipose tissue and the dysfunction and/or limita-
tions of other body organs (25–27). Adiposopathy is
a term used to describe pathogenic adipose tissue
whose adverse clinical consequences may be promo-
ted and exacerbated by adipocyte hypertrophy, vis-
ceral adipose tissue accumulation, and sedentary
lifestyle in genetically and environmentally suscept-
ible patients, and which represents an underlying,
root physiological process leading to metabolic dis-
eases such as type 2 diabetes mellitus, hypertension
and dyslipidaemia. The results of this survey study
demonstrate that while generally and directly associ-
ated with one another, the relationship between BMI
and metabolic disease is not an absolute one, and
further lends support to the adipocentric paradigm
wherein pathologenic adipose tissue (adiposopathy)
is a more rational treatment target than BMI (adi-
posity) alone (23).
With regard to the survey itself, the SHIELD study
represents the largest such initiative ever taken. How-
ever, consumer panel surveys such as SHIELD do
have limitations. First of all, SHIELD relied only on
self-reporting of medical data without clinical or
laboratory conﬁrmation. Furthermore, only a small
percentage (5–8%) of consumers initially invited to
participate in the NFO panel (the step prior to mail-
ing of the screener questionnaire) elect to do so,
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tion. Also, household panels also tend to under-rep-
resent the very wealthy and very poor segments of
the population, and do not include military or insti-
tutionalised individuals (6,28). However, NFO survey
response rates are generally high (60–75%) and the
demography of non-responders is known and can be
controlled for in analyses. Another potential con-
founder includes the potential for misreporting of
parameters such as height and weight in a self-repor-
ted survey.
Nonetheless, this report demonstrates that a self-
reported survey can often acquire data that reason-
ably approximates surveys that also include clinical
and laboratory evaluations. This is important because
population assessments of the frequency of the asso-
ciations of obesity with metabolic diseases such as
diabetes mellitus, hypertension and dyslipidaemia
have great epidemiological value, but are impaired
by the logistical difﬁculties in obtaining reasonable
and reliable data to make these assessments. For the
SHIELD screener survey, a large number of question-
naires were sent, with a high return rate (64%), pro-
viding a sample that is generally representative of the
overall US population. Thus, the SHIELD survey
appeared to be a relatively cost-effective method to
collect data on many aspects of the relationship of
self-reported data and metabolic diseases.
Another potential utility of a self-reported survey
is that the use of a volunteer panel that is accus-
tomed to completing surveys also allows for the col-
lection of much data that are otherwise difﬁcult to
collect (e.g. quality-of-life data for those with diabe-
tes mellitus). Furthermore, longitudinal surveys are
more easily obtained. For example, subsamples of the
SHIELD screener respondents are currently under
way, using a longer, more detailed survey assessing
individual health status, health knowledge, and atti-
tudes as well as current behaviours and treatments.
Annual follow-up assessments are planned over the
next 4 years, which will allow further exploration of
relationships between these variables and metabolic
diseases.
The SHIELD screener was a useful tool to identify
individuals with metabolic risk factors. Mailed con-
sumer panel surveys such as this one may represent
a timely alternative to in-person interviews and
examinations for identifying populations with certain
conditions, such as diabetes mellitus, but may be less
useful for others, such as dyslipidaemia.
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